The risk of developing coronary artery disease or congestive heart failure, and overall mortality in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis - Pantalone, K M; Katalan, M W; Yu, C (Acta Diabetol, 2009)
et al